Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track GRDX with free AI briefings, catalyst countdowns, and dilution alerts.

GRDX · GridAI Technologies Corp.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

On the Downside Radar. Closed at $3.30, 43% below $5.76, its close on the day of its Oct 28 private placement. Of biotech stocks this far below their close on the day of a recent offering, 76% were lower 60 trading days later (median -29%). How we know
$1.4M Cash on Hand
2.5mo Cash Runway
Follow GRDX by email Get an email when GRDX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about GRDX, unsubscribe in one click. Privacy

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

💰 Cash Runway & Dilution Risk

GRDX holds $1.4M in cash and short-term investments (as of Jun 30, 2026) and burns about $1.6M/quarter from operations, an estimated runway of 2.5 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 65 · High

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when GRDX files for a raise →

👥 Who Owns GRDX

Insiders 17.7% Other 5%+ holders 2% Institutions (18 holders) 8.7% Public and other holders 71.6%
HolderTypeShares% of sharesAs of
Jason David Sawyer
Chief Executive Officer, Director, 10% o
Insider 1,080,000 10.52% 2026-10-26
Strategic EP, LLC 5%+ holder (13G) 209,541 2.04% 2026-01-12
Edward Borkowski
Director
Insider 177,327 1.73% 2026-10-26
Anna Skowron
Interim CFO · +175,000 options
Insider 140,000 1.36% 2026-10-26
Geordan Garrett Pursglove
Director
Insider 140,000 1.36% 2026-10-26
Jack Syage
Director · +4,920 options
Insider 80,000 0.78% 2026-10-26
Manpreet Uppal
Former director
Insider 60,000 0.58% 2026-10-19
James Sapirstein
Chairman and CEO, Director
Insider 35,816 0.35% 2024-07-02
Chaitan Phd Khosla
Director · +53,121 options
Insider 25,329 0.25% 2024-06-11
Alastair Riddell
Director
Insider 20,240 0.20% 2024-01-02
Mary Theresa Coelho
Director
Insider 20,237 0.20% 2024-01-02
Charles J Casamento
Director
Insider 19,937 0.19% 2024-01-02

Share count 10,265,090 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full GRDX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for GRDX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.